We’ve achieved this through innovations in science and robotics to create widespread testing capacity and same-day/accurate results at a cost that easily allows for high-frequency testing.
This combination enables us to deliver meaningful impact to our nation’s schools, government, hospitals, and corporations in combating this pandemic—and all future diagnostic testing needs.
FirmaLab utilizes scientific innovation and industry-leading lab automation expertise to process thousands of tests a day with 99% of results received in < 24 hours instead of the industry average 48-72 hours. FirmaLab uses top-of-the-line lab robotics that process PCR and next-generation variant detection in parallel within a single lab.
FirmaLab utilizes a real-time RT-PCR molecular test for the SARS-Cov2 virus that causes the COVID-19 respiratory syndrome. This test is also designed to rule out Influenza and Respiratory Syncytial Virus that have common symptoms to COVD-19.
Virus Pathogen Targets:
Influenza A
Influenza B
Flu A Typing
SARS-CoV-2a
SARS-CoV-2b (COVID-19)
Full Respiratory Panel Targets:
Influenza A Virus
Influenza B Virus
Respiratory Syncytial Virus A/B
SARS-CoV-2
Adenovirus
Human Metapneumovirus
Rhinovirus
Parainfluenza Virus 1/2/3/4
STI Pathogen Detection:
Bacterial Vaginosis
Candida Vaginitis
Trichomonas Vaginalis
Chlamydia Trachomatis
Neisseria Gonorrhoeae
HPV 16/18/45
HSV 1&2
HPV
Mycoplasma Genitalium
Hepatitis B Virus
Hepatitis C Virus
HIV-1
As part of our response to the COVID-19 pandemic, the scientific team at FirmaLab developed the UDX SARS-CoV2 Molecular Assay, a laboratory developed test (LDT), and received our Emergency Use Authorization (EUA) from the FDA.
Gold-standard accuracy with same-day results, costing 50% national average
COVID -19 RT-PCR TESTING MOLECULAR TEST
The FirmaLab SARS-CoV-2 Molecular Assay is a real-time RT-PCR test intended for the presumptive qualitative detection of nucleic acid of SARS-CoV-2 from upper and lower respiratory specimens. PCR (polymerase chain reaction) is a method to analyze a short sequence of DNA (or RNA) even in samples containing only minute quantities of DNA or RNA. PCR is used to reproduce (amplify) selected sections of DNA or RNA. PCR is highly efficient in that untold numbers of copies can be made of the DNA. Moreover, PCR uses the same molecules that nature uses for copying DNA. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out a bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.
By rapidly adding capacity, instrumentation, equipment and staff to meet the unprecedented demand for testing. FirmaLab will have the capacity to do 10,000 tests per day with a 24-hour turnaround time.
COVID -19 IgG ANTIBODY TEST SEROLOGY TEST
FirmaLab serology test identifies the presence of antibodies that indicate that a person had an immune response to COVID-19 (also known as coronavirus or SARS-CoV-2). A positive result of this antibody (IgG) test indicates previous exposure to COVID-19 and the body has developed antibodies. Although It may take up to 14 days after the onset of symptoms for antibodies to be developed within the body, 91% of people develop such antibodies within the first 8-13 days. Some people infected with COVID-19 will never exhibit symptoms but will have a detectable antibody response. While there is a belief that the presence of antibodies may provide immunity to future infections, there is not yet enough data to state this conclusively. These tests can give greater detail into the prevalence of a disease in a population by identifying the individuals who have developed these antibodies.
All Rights Reserved | Firmalab Inc.